The role of pramlintide for weight loss - PubMed
Based on preliminary evidence, pramlintide facilitates modest weight loss in obese or overweight patients with and without diabetes. However, current trials were limited by inconsistent study design, dosing, and patient population.
Enhanced Weight Loss With Pramlintide/Metreleptin: An …
Combination treatment with pramlintide/metreleptin led to significantly greater weight loss from enrollment to week 20 (−12.7 ± 0.9%; least squares mean ± s.e.) than treatment with pramlintide (−8.4 ± 0.9%; P < 0.001) or metreleptin (−8.2 ± 1.3%; P < 0.01) alone (evaluable, N = 93).
Sustained Weight Loss Following 12-Month Pramlintide …
Jan 4, 2008 · RESEARCH DESIGN AND METHODS —In a 4-month, double-blind, placebo-controlled, dose-ranging study, 411 obese subjects were randomized to receive pramlintide (six arms: 120, 240, and 360 μg b.i.d. and t.i.d.) or placebo in conjunction with a structured LSI program geared toward weight loss.
Pramlintide in the Management of Insulin-Using Patients with Type …
Feb 3, 2006 · Clinical studies have demonstrated that pramlintide reduces postprandial glucose concentrations through at least three distinct mechanisms of action including modulation of gastric emptying, prevention of abnormal postprandial glucagon secretion, and increased satiety leading to a reduction in caloric intake.
Enhanced Weight Loss With Pramlintide/Metreleptin: An …
Sep 6, 2012 · Combination treatment with pramlintide/metreleptin led to significantly greater weight loss from enrollment to week 20 (−12.7 ± 0.9%; least squares mean ± s.e.) than treatment with pramlintide (−8.4 ± 0.9%; P < 0.001) or metreleptin (−8.2 …
Pramlintide treatment reduces 24-h caloric intake and meal sizes …
Aug 1, 2007 · Herein, we provide the first detailed assessment of the anorexigenic mechanism of action underlying pramlintide's weight-lowering effect in obese humans.
Amylin Replacement With Pramlintide in Type 1 and Type 2 …
Jul 1, 2002 · Adjunctive therapy with pramlintide, a synthetic analog of the human amylin hormone, facilitates a significant improvement of postprandial and overall glycemic control in patients with either type 1 or type 2 diabetes without an …
Pramlintide - an overview | ScienceDirect Topics
Pramlintide is a modified form of amylin, a peptide secreted from the β-cell of the pancreas along with insulin. Pramlintide has been approved by the FDA for treatment of diabetes and in clinical trials produced weight loss.
Enhanced weight loss with pramlintide/metreleptin: an …
The neurohormonal control of body weight involves a complex interplay between long-term adiposity signals (e.g., leptin), and short-term satiation signals (e.g., amylin). In diet-induced obese (DIO) rodents, amylin/leptin combination treatment led to …
Pramlintide: Clinical Strategies for Success | Diabetes Spectrum ...
Jan 1, 2010 · These three important actions of pramlintide offer patients with diabetes who have been prescribed mealtime insulin the chance for improved glucose control without subsequent weight gain, and, in some cases, with weight loss by replacing the “other” β-cell hormone (amylin), which is deficient along with insulin.